Cell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted

MaxCyte

14/10/2026 13:14

Overview
Cell-engineering firm's preliminary Q3 revenue rose 26% yr/yr, beating analyst expectations
Company raised full-year 2026 revenue guidance to about $34 mln
Q3 results driven by accelerated instrument purchasing from a large customer

Outlook
MaxCyte raises 2026 revenue guidance to about $34 mln from $30-32 mln
Company expects 2026 core business revenue of about $28 mln, up from $25-27 mln prior guidance
MaxCyte sees 2026 SPL Program-related revenue at about $6 mln, up from $5 mln prior view

Result Drivers
ACCELERATED PURCHASING - Co said Q3 results were driven by accelerated instrument purchasing from a large customer
MILESTONE REVENUE - Co recognized milestone revenue from SPL partner in Q3, its second milestone achieved in 2026

Company press release: ID:nGNX5TRFTw

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$8.10 mln
$7.05 mln (5 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 366.7% above its October 13 closing price of $0.96

Reuters Recommended Reads
Oct 12 - Nurix Therapeutics Q3 swings to profit on Roche collaboration

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)